Infectious diseases are generated by microorganisms such as fungi, viruses, bacteria, and other organism species. Infectious disease diagnostics are the methods utilized by hospitals, clinical laboratories, and others to detect or identify foreign antigens/organisms by using several diagnostic tests. These tests assist in the identification of the kind of pathogen. Also, the level of the degree to which the disease is spread in the body. The diagnostic procedure may be sent with the aid of conventional diagnostic tests or point-of-care testing tools. Growth of the global infectious disease diagnostic market is majorly driven by increase in prevalence of infectious disease such as hepatitis, influenza, COVID-19, & human immuno deficiency virus (HIV); rise in demand for point-of-care diagnostic test; increase in funding from private & government organizations for diagnostic service centers; and advancements in technologies in the field of infectious disease diagnostics. However, high cost associated with diagnostic instruments and lack of skilled technicians in the global market is hampering market growth.
F.Hoffmann-La Roche ltd. and Abbott Laboratories – Notable Market Players in Infectious Disease Diagnostics Market
The infectious disease diagnostics market is majorly comprised of top players involving F.Hoffmann-La Roche, Ltd.; Danaher Corporation; BD; bioMérieux SA; AccuBioTech Co., Ltd.; Bio-Rad Laboratories, Inc.; ACON Laboratories, Inc.; Abbott; Trinity Biotech; and Cardinal Health, Inc. among others.
The companies listed above are implementing various strategies such as product launches, acquisitions, mergers, and partnerships, which have resulted in the company’s growth and, in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.
Below is the list of the growth strategies done by the players operating in the infectious disease diagnostics market:
| Year | News |
| Jan-2022 | Cepheid announced that Health Canada has issued Cepheid a medical device license for Xpert Xpress CoV-2/Flu/RSV plus, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, Flu B, and respiratory syncytial virus (RSV) infections from a single patient sample. |
| Feb-2022 | F.Hoffmann-La Roche Ltd announced the expansion of the COVID-19 PCR portfolio to the cobas 5800 System, a recently launched molecular laboratory instrument, in countries accepting the CE mark. These include cobas SARS-CoV-2 Qualitative and cobas SARS-CoV-2 & Influenza A/B tests. |
| Nov-2020 | bioMérieux, a world leader in in vitro diagnostic solutions for infectious disease, is pleased to announce CLARION, its pioneering clinical informatics software that connects diagnostic data in the United States of America. The announcement coincides with World Antimicrobial Awareness Week and reflects bioMerieux’s goal to provide multiple solutions to combat antibiotic overuse and inappropriate use worldwide. |
| May-2020 | Bio-Rad Laboratories Inc., announced that its SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit has been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). The SARS-CoV-2 Droplet Digital PCR (ddPCR) test runs on Bio-Rad’s QX200 and QXDx ddPCR systems. |
| Jun-2021 | Bio-Rad Laboratories, Inc., announced the launch of its PREvalence ddPCR SARS-CoV-2 Wastewater Quantification Kit, a sensitive, accurate, and cost-effective tool used to detect SARS-CoV-2 in a community’s wastewater. |
